Stay updated on Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.

Latest updates to the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a minor site maintenance update: addition of Revision: v3.4.2 and removal of the older funding-related note (Revision: v3.4.1); no changes to core study details, eligibility, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated the revision tag to v3.4.1, replacing the previous v3.4.0.SummaryDifference0.1%

- Check28 days agoChange DetectedA glossary display option was added and several study metadata fields were updated (e.g., Results First Posted and Last Update Posted). The older estimated fields and No FEAR Act data were removed, and the site version updated to Revision: v3.4.0.SummaryDifference0.1%

- Check35 days agoChange Detected- Removed sponsor branding (Bristol-Myers Squibb / BMS) and access to key study documents/links (PDF; 'Helpful Links Provided by'). This reduces visibility of sponsor information and availability of official materials on the Study Details page.SummaryDifference18%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe Locations section was updated to add numerous new sites across the United States, Argentina, Australia, Chile, and other countries, while many existing sites were removed. This changes which sites are available for participant enrollment and may affect recruitment timelines.SummaryDifference3%

Stay in the know with updates to Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.